Lead Sponsor

University Hospital, Ghent

Age

18 - 80 years

Sex

MALE

Healthy Volunteers

No

•Histologically proven diagnosis of prostate cancer (PCa)
•Biochemical relapse of PCa following radical local prostate treatment
•N1 and M1a/b disease on imaging, with a combined maximum of 3 synchronous lesions.
•World Health Organization (WHO) performance state 0-1
•Exclusion of local relapse
•Age \>=18 years old
•Signed informed consent

•Serum testosterone level \<50ng/ml
•Symptomatic metastases
•PSA rise while on active treatment with luteinizing hormone-releasing hormone (LHRH)-agonist, LHRH-antagonist, anti-androgen, maximal androgen blockade, oestrogen
•Previous treatment with cytotoxic agent for PCa
•Treatment during the past month with products known to influence Prostate Specific Antigen (PSA) levels (e.g. fluconazole, finasteride, corticosteroids,…)
•Disorder precluding understanding of trial information or informed consent